NasdaqGS - Delayed Quote • USD
Sarepta Therapeutics, Inc. (SRPT)
At close: 4:00 PM EDT
After hours: 4:01 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 14 |
| Avg. Estimate | -0.06 | 1.07 | 3.61 | 11.54 |
| Low Estimate | -0.43 | 0.04 | 0.9 | 1.33 |
| High Estimate | 0.54 | 2.59 | 6.3 | 25.35 |
| Year Ago EPS | -0.27 | -0.46 | -5.8 | 3.61 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 15 | 19 | 19 |
| Avg. Estimate | 384.67M | 501.82M | 1.9B | 2.88B |
| Low Estimate | 365.6M | 415.5M | 1.66B | 1.8B |
| High Estimate | 435M | 705.54M | 2.42B | 4.4B |
| Year Ago Sales | 261.24M | 331.82M | 1.24B | 1.9B |
| Sales Growth (year/est) | 47.20% | 51.20% | 52.90% | 51.60% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.78 | -1.23 | 0.01 | -0.07 |
| EPS Actual | -0.27 | -0.46 | 0.47 | 0.37 |
| Difference | 1.51 | 0.77 | 0.46 | 0.44 |
| Surprise % | 84.80% | 62.60% | 4,600.00% | 628.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.06 | 1.07 | 3.61 | 11.54 |
| 7 Days Ago | -0.13 | 0.62 | 2.42 | 10.39 |
| 30 Days Ago | -0.07 | 0.73 | 2.43 | 11.04 |
| 60 Days Ago | -0.06 | 0.72 | 2.13 | 10.16 |
| 90 Days Ago | 0.44 | 0.87 | 2.98 | 10.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 3 | 4 |
| Up Last 30 Days | 9 | 10 | 12 | 10 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | SRPT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 77.80% | -- | -- | 8.60% |
| Next Qtr. | 332.60% | -- | -- | 11.90% |
| Current Year | 162.20% | -- | -- | 5.60% |
| Next Year | 219.70% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 96.00% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 5/3/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 5/2/2024 |
| Reiterates | Needham: Buy to Buy | 5/2/2024 |
| Maintains | UBS: Buy to Buy | 3/1/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 2/29/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 2/29/2024 |
Related Tickers
MDGL Madrigal Pharmaceuticals, Inc.
206.92
-0.54%
APLS Apellis Pharmaceuticals, Inc.
42.52
+0.52%
BPMC Blueprint Medicines Corporation
108.34
-0.40%
VKTX Viking Therapeutics, Inc.
80.20
+0.36%
AXSM Axsome Therapeutics, Inc.
73.68
-2.64%
CTMX CytomX Therapeutics, Inc.
2.0400
-51.31%
VRTX Vertex Pharmaceuticals Incorporated
418.99
+0.04%
REGN Regeneron Pharmaceuticals, Inc.
968.00
+1.28%
ALNY Alnylam Pharmaceuticals, Inc.
151.37
-0.60%
JANX Janux Therapeutics, Inc.
51.94
-6.19%